Managing PCOS with Elevated DHEA/DHEAS Levels

Understanding DHEA/DHEAS Elevation in PCOS

The American Academy of Dermatology recommends measuring DHEA/DHEAS only in patients with clinical features suggesting hyperandrogenism, such as prepubertal acne with early body odor, axillary/pubic hair, accelerated growth, or postpubertal females with infrequent menses, severe hirsutism, androgenetic alopecia, or recalcitrant acne 1
A typical hormone screening panel includes DHEAS along with free and total testosterone, androstenedione, LH, and FSH to exclude nonclassical congenital adrenal hyperplasia and other causes of androgen excess 1
Measure 17-hydroxyprogesterone to exclude congenital adrenal hyperplasia if DHEAS is markedly elevated 2

The American College of Physicians recommends initiating multicomponent lifestyle intervention before or concurrent with pharmacologic therapy 2, 3
Target just 5% weight loss, which improves metabolic parameters, ovulation rates, and pregnancy outcomes 4, 5, 2, 3
Implement diet, exercise, and behavioral strategies together 2, 3

The American College of Obstetricians and Gynecologists recommends using combination oral contraceptive pills (OCPs) as first-line treatment to regulate menstrual cycles, provide endometrial protection, and suppress ovarian androgen secretion 5, 2
OCPs may increase triglycerides and HDL cholesterol but do not increase cardiovascular events compared to the general population 5, 3
Use metformin as the preferred insulin-sensitizing agent when pharmacologic intervention is warranted 2, 3
Metformin decreases circulating androgens (including those of adrenal origin) through improved insulin sensitivity 3
Metformin improves glucose tolerance over time and tends to decrease weight 4, 3

The American Society for Reproductive Medicine recommends beginning with weight control and regular exercise 4, 2
Use clomiphene citrate as first-line ovulation induction—approximately 80% ovulate and 50% conceive 4, 5, 2
If clomiphene fails, use low-dose gonadotropin therapy to minimize ovarian hyperstimulation risk 4, 5, 2

The Endocrine Society recommends performing 2-hour oral glucose tolerance test with 75-gram glucose load to detect type 2 diabetes and glucose intolerance 5, 2, 3
Obtain fasting lipid profile (total cholesterol, LDL, HDL, triglycerides) as insulin resistance drives atherogenic dyslipidemia 2, 3
Check TSH to exclude thyroid disease 2
Measure prolactin to exclude hyperprolactinemia 2
Monitor blood pressure regularly due to increased cardiovascular disease risk 5
Look for acanthosis nigricans on physical exam, indicating underlying insulin resistance 5, 2, 3

Metformin is superior to thiazolidinediones, which increase weight and have less favorable risk-benefit profiles 3
Insulin resistance in PCOS creates a particularly atherogenic lipid profile requiring monitoring regardless of normal DHEA/DHEAS levels 3
While typically indicating insulin resistance, acanthosis nigricans may rarely indicate associated insulinoma or gastric adenocarcinoma 3

The American Heart Association recommends at least 250 minutes per week of moderate-intensity activity or 150 minutes per week of vigorous activity, plus muscle-strengthening exercises on 2 non-consecutive days per week for weight loss in PCOS patients 6, 7
Reducing soft drinks, fruit juices, and sugar-sweetened beverages is recommended for weight loss and metabolic improvement in PCOS patients 6, 7
Incorporating goal-setting, self-monitoring, stimulus control, problem-solving, assertiveness training, slower eating, reinforcement of changes, and relapse prevention strategies is essential for behavioral changes in PCOS patients 6, 7
Addressing weight-related stigma, negative body image, and low self-esteem is crucial when discussing weight management with PCOS patients 6, 7

The Endocrine Society suggests considering GLP-1 receptor agonists (semaglutide, liraglutide) for weight loss and metabolic improvement in PCOS patients if lifestyle modifications plus metformin prove insufficient after 3-6 months 8
GLP-1 receptor agonists are particularly valuable for PCOS patients with BMI ≥27 with comorbidities or ≥30 without comorbidities 8